VTCN1 anticorps (PerCP-Cy5.5)

N° du produit ABIN2659922

Détail du produit anti-VTCN1 anticorps (PerCP-Cy5.5)

Antigène: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VTCN1 est conjugé à/à la PerCP-Cy5.5

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Clone: MIH43

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur VTCN1

Antigène: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Autre désignation: B7-H4 (VTCN1 Produits)

Synonymes: anticorps B7h4, anticorps B7s1, anticorps B7x, anticorps BC032925, anticorps B7-H4, anticorps B7H4, anticorps B7S1, anticorps B7X, anticorps B7h.5, anticorps PRO1291, anticorps VCTN1, anticorps RGD1311204, anticorps V set domain containing T cell activation inhibitor 1 L homeolog, anticorps V-set domain containing T cell activation inhibitor 1, anticorps V-set domain containing T-cell activation inhibitor 1, anticorps V set domain containing T cell activation inhibitor 1, anticorps vtcn1.L, anticorps VTCN1, anticorps vtcn1, anticorps Vtcn1

Sujet: B7-H4, also known as VTCN1, is a type I transmembrane protein and member of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.